Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels
Background It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG)...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2017-02, Vol.52 (2), p.237-244 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 2 |
| container_start_page | 237 |
| container_title | Journal of gastroenterology |
| container_volume | 52 |
| creator | Miyake, Teruki Hirooka, Masashi Yoshida, Osamu Furukawa, Shinya Kumagi, Teru Koizumi, Mitsuhito Yamamoto, Shin Kuroda, Taira Arimitsu, Eiji Takeshita, Eiji Abe, Masanori Kitai, Kohichiro Matsuura, Bunzo Hiasa, Yoichi |
| description | Background
It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels.
Methods
This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18–80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG.
Results
Onset of IFG was found in 7.7 % of men and 2.1 % of women (
p
|
| doi_str_mv | 10.1007/s00535-016-1234-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1868313025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714583769</galeid><sourcerecordid>A714583769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-fa96be0423c134073c78b4fcd7ecb8b7aa1d1a6e894a909dbef7c110d7d97e683</originalsourceid><addsrcrecordid>eNqNkk1rFTEYhYMo9lr9AW4k4MbN1HzNZLIs9RMKbnQdMpk319RMck0yxf57M9xaP1CQLALnfc4hbzgIPaXkjBIiXxZCet53hA4dZVx06h7aUdGUXjF2H-2IEqKjVIoT9KiUK0IoJ_34EJ0wyQWjTO7Qt1feOcgQLRTsI66fAWdfvuDksDO13uDgryFjlzJOsUDdBn45GJ9hbkSpPu7xPqw2FcDG2pTnTakJT6ZA8BHwIZiymDsowDWE8hg9cCYUeHJ7n6JPb15_vHjXXX54-_7i_LKzQg21c0YNExDBuKVcEMmtHCfh7CzBTuMkjaEzNQOMShhF1DyBk5ZSMstZSRhGfopeHHMPOX1doVS9-GIhBBMhrUXTsUHtX1j_HygbJCVcqoY-_wO9SmuObZEtsGf9oPjwk9qbANpHl2o2dgvV55KKfuRy2LLO_kK1M8PibYrgfNN_M9CjweZUSganD9kvJt9oSvRWDH0shm7F0Fsx9OZ5dvvgdVpgvnP8aEID2BEobRT3kH_Z6J-p3wHyKcJK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1865256936</pqid></control><display><type>article</type><title>Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Miyake, Teruki ; Hirooka, Masashi ; Yoshida, Osamu ; Furukawa, Shinya ; Kumagi, Teru ; Koizumi, Mitsuhito ; Yamamoto, Shin ; Kuroda, Taira ; Arimitsu, Eiji ; Takeshita, Eiji ; Abe, Masanori ; Kitai, Kohichiro ; Matsuura, Bunzo ; Hiasa, Yoichi</creator><creatorcontrib>Miyake, Teruki ; Hirooka, Masashi ; Yoshida, Osamu ; Furukawa, Shinya ; Kumagi, Teru ; Koizumi, Mitsuhito ; Yamamoto, Shin ; Kuroda, Taira ; Arimitsu, Eiji ; Takeshita, Eiji ; Abe, Masanori ; Kitai, Kohichiro ; Matsuura, Bunzo ; Hiasa, Yoichi</creatorcontrib><description>Background
It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels.
Methods
This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18–80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG.
Results
Onset of IFG was found in 7.7 % of men and 2.1 % of women (
p
< 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316–2.534,
p
< 0.001; women: aHR 2.016, 95 % CI 1.117–3.6,
p
= 0.02].
Conclusions
Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-016-1234-9</identifier><identifier>PMID: 27342127</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies ; Biliary Tract ; Blood Glucose - metabolism ; Cohort Studies ; Colorectal Surgery ; Development and progression ; Dextrose ; Fasting ; Fatty liver ; Fatty Liver - complications ; Female ; Gastroenterology ; Glucose ; Glucose Intolerance - etiology ; Glucose Tolerance Test ; Hepatitis B ; Hepatitis B virus ; Hepatitis C virus ; Hepatology ; Humans ; Hypoglycemic agents ; Liver ; Longitudinal Studies ; Male ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Middle Aged ; Original Article—Liver ; Pancreas ; Retrospective Studies ; Risk Factors ; Surgical Oncology ; Type 2 diabetes ; Uric acid ; Viral antibodies ; Young Adult</subject><ispartof>Journal of gastroenterology, 2017-02, Vol.52 (2), p.237-244</ispartof><rights>Japanese Society of Gastroenterology 2016</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Journal of Gastroenterology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-fa96be0423c134073c78b4fcd7ecb8b7aa1d1a6e894a909dbef7c110d7d97e683</citedby><cites>FETCH-LOGICAL-c496t-fa96be0423c134073c78b4fcd7ecb8b7aa1d1a6e894a909dbef7c110d7d97e683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-016-1234-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-016-1234-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27342127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyake, Teruki</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Yoshida, Osamu</creatorcontrib><creatorcontrib>Furukawa, Shinya</creatorcontrib><creatorcontrib>Kumagi, Teru</creatorcontrib><creatorcontrib>Koizumi, Mitsuhito</creatorcontrib><creatorcontrib>Yamamoto, Shin</creatorcontrib><creatorcontrib>Kuroda, Taira</creatorcontrib><creatorcontrib>Arimitsu, Eiji</creatorcontrib><creatorcontrib>Takeshita, Eiji</creatorcontrib><creatorcontrib>Abe, Masanori</creatorcontrib><creatorcontrib>Kitai, Kohichiro</creatorcontrib><creatorcontrib>Matsuura, Bunzo</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><title>Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background
It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels.
Methods
This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18–80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG.
Results
Onset of IFG was found in 7.7 % of men and 2.1 % of women (
p
< 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316–2.534,
p
< 0.001; women: aHR 2.016, 95 % CI 1.117–3.6,
p
= 0.02].
Conclusions
Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.</description><subject>Abdominal Surgery</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies</subject><subject>Biliary Tract</subject><subject>Blood Glucose - metabolism</subject><subject>Cohort Studies</subject><subject>Colorectal Surgery</subject><subject>Development and progression</subject><subject>Dextrose</subject><subject>Fasting</subject><subject>Fatty liver</subject><subject>Fatty Liver - complications</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Glucose</subject><subject>Glucose Intolerance - etiology</subject><subject>Glucose Tolerance Test</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatitis C virus</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Hypoglycemic agents</subject><subject>Liver</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Original Article—Liver</subject><subject>Pancreas</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Surgical Oncology</subject><subject>Type 2 diabetes</subject><subject>Uric acid</subject><subject>Viral antibodies</subject><subject>Young Adult</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkk1rFTEYhYMo9lr9AW4k4MbN1HzNZLIs9RMKbnQdMpk319RMck0yxf57M9xaP1CQLALnfc4hbzgIPaXkjBIiXxZCet53hA4dZVx06h7aUdGUXjF2H-2IEqKjVIoT9KiUK0IoJ_34EJ0wyQWjTO7Qt1feOcgQLRTsI66fAWdfvuDksDO13uDgryFjlzJOsUDdBn45GJ9hbkSpPu7xPqw2FcDG2pTnTakJT6ZA8BHwIZiymDsowDWE8hg9cCYUeHJ7n6JPb15_vHjXXX54-_7i_LKzQg21c0YNExDBuKVcEMmtHCfh7CzBTuMkjaEzNQOMShhF1DyBk5ZSMstZSRhGfopeHHMPOX1doVS9-GIhBBMhrUXTsUHtX1j_HygbJCVcqoY-_wO9SmuObZEtsGf9oPjwk9qbANpHl2o2dgvV55KKfuRy2LLO_kK1M8PibYrgfNN_M9CjweZUSganD9kvJt9oSvRWDH0shm7F0Fsx9OZ5dvvgdVpgvnP8aEID2BEobRT3kH_Z6J-p3wHyKcJK</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Miyake, Teruki</creator><creator>Hirooka, Masashi</creator><creator>Yoshida, Osamu</creator><creator>Furukawa, Shinya</creator><creator>Kumagi, Teru</creator><creator>Koizumi, Mitsuhito</creator><creator>Yamamoto, Shin</creator><creator>Kuroda, Taira</creator><creator>Arimitsu, Eiji</creator><creator>Takeshita, Eiji</creator><creator>Abe, Masanori</creator><creator>Kitai, Kohichiro</creator><creator>Matsuura, Bunzo</creator><creator>Hiasa, Yoichi</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels</title><author>Miyake, Teruki ; Hirooka, Masashi ; Yoshida, Osamu ; Furukawa, Shinya ; Kumagi, Teru ; Koizumi, Mitsuhito ; Yamamoto, Shin ; Kuroda, Taira ; Arimitsu, Eiji ; Takeshita, Eiji ; Abe, Masanori ; Kitai, Kohichiro ; Matsuura, Bunzo ; Hiasa, Yoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-fa96be0423c134073c78b4fcd7ecb8b7aa1d1a6e894a909dbef7c110d7d97e683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Abdominal Surgery</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies</topic><topic>Biliary Tract</topic><topic>Blood Glucose - metabolism</topic><topic>Cohort Studies</topic><topic>Colorectal Surgery</topic><topic>Development and progression</topic><topic>Dextrose</topic><topic>Fasting</topic><topic>Fatty liver</topic><topic>Fatty Liver - complications</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Glucose</topic><topic>Glucose Intolerance - etiology</topic><topic>Glucose Tolerance Test</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatitis C virus</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Hypoglycemic agents</topic><topic>Liver</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Original Article—Liver</topic><topic>Pancreas</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Surgical Oncology</topic><topic>Type 2 diabetes</topic><topic>Uric acid</topic><topic>Viral antibodies</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyake, Teruki</creatorcontrib><creatorcontrib>Hirooka, Masashi</creatorcontrib><creatorcontrib>Yoshida, Osamu</creatorcontrib><creatorcontrib>Furukawa, Shinya</creatorcontrib><creatorcontrib>Kumagi, Teru</creatorcontrib><creatorcontrib>Koizumi, Mitsuhito</creatorcontrib><creatorcontrib>Yamamoto, Shin</creatorcontrib><creatorcontrib>Kuroda, Taira</creatorcontrib><creatorcontrib>Arimitsu, Eiji</creatorcontrib><creatorcontrib>Takeshita, Eiji</creatorcontrib><creatorcontrib>Abe, Masanori</creatorcontrib><creatorcontrib>Kitai, Kohichiro</creatorcontrib><creatorcontrib>Matsuura, Bunzo</creatorcontrib><creatorcontrib>Hiasa, Yoichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyake, Teruki</au><au>Hirooka, Masashi</au><au>Yoshida, Osamu</au><au>Furukawa, Shinya</au><au>Kumagi, Teru</au><au>Koizumi, Mitsuhito</au><au>Yamamoto, Shin</au><au>Kuroda, Taira</au><au>Arimitsu, Eiji</au><au>Takeshita, Eiji</au><au>Abe, Masanori</au><au>Kitai, Kohichiro</au><au>Matsuura, Bunzo</au><au>Hiasa, Yoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>52</volume><issue>2</issue><spage>237</spage><epage>244</epage><pages>237-244</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background
It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels.
Methods
This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18–80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG.
Results
Onset of IFG was found in 7.7 % of men and 2.1 % of women (
p
< 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316–2.534,
p
< 0.001; women: aHR 2.016, 95 % CI 1.117–3.6,
p
= 0.02].
Conclusions
Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>27342127</pmid><doi>10.1007/s00535-016-1234-9</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2017-02, Vol.52 (2), p.237-244 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1868313025 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Abdominal Surgery Adolescent Adult Aged Aged, 80 and over Antibodies Biliary Tract Blood Glucose - metabolism Cohort Studies Colorectal Surgery Development and progression Dextrose Fasting Fatty liver Fatty Liver - complications Female Gastroenterology Glucose Glucose Intolerance - etiology Glucose Tolerance Test Hepatitis B Hepatitis B virus Hepatitis C virus Hepatology Humans Hypoglycemic agents Liver Longitudinal Studies Male Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Original Article—Liver Pancreas Retrospective Studies Risk Factors Surgical Oncology Type 2 diabetes Uric acid Viral antibodies Young Adult |
| title | Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A16%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20the%20risk%20of%20fatty%20liver%20for%20onset%20of%20impaired%20fasting%20glucose%20according%20to%20baseline%20plasma%20glucose%20levels&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Miyake,%20Teruki&rft.date=2017-02-01&rft.volume=52&rft.issue=2&rft.spage=237&rft.epage=244&rft.pages=237-244&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-016-1234-9&rft_dat=%3Cgale_proqu%3EA714583769%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1865256936&rft_id=info:pmid/27342127&rft_galeid=A714583769&rfr_iscdi=true |